Vascular surgeons play a crucial role in combating cardiovascular diseases through revascularization procedures, aiming to restore blood flow to compromised regions of the body. From vein grafts to arteriovenous fistulas (AVFs), these interventions are lifelines for patients facing heart failure or kidney dysfunction. However, despite their significance, challenges persist.

The longevity of revascularizations is often hindered by issues such as cell build-up within vessels, necessitating repeated surgeries—a costly and burdensome cycle for patients. Enter nanomedicine, a burgeoning field offering innovative solutions. Researchers at UVA Health are pioneering a groundbreaking technique called epiNanopaint, which promises to revolutionize revascularization care.

By applying adhesive nanoparticles infused with drugs during initial surgeries, epiNanopaint aims to prevent clogged vessels and the subsequent need for frequent interventions. Targeting the enzyme DOT1L, these nanoparticles act as protective guards, ensuring prolonged drug release at the site of need. If successful, this approach could transform treatment paradigms, sparing patients from repeated surgeries and alleviating financial burdens.

Dr. Lian-Wang Guo, a leading figure in this research, emphasizes the potential impact: «Our approach is like deploying tiny guards to protect blood vessels from going bad, so that there is no need to open the body over and over again to repair them.» With the potential to enhance patient outcomes and reduce healthcare costs, nanomedicine offers hope for a brighter future in cardiovascular care.

Article written by HospiMedica



Hospi Medica